End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
42.65
CNY
|
-1.20%
|
|
+3.70%
|
-11.15%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
24,006
|
27,487
|
50,923
|
35,990
|
21,188
|
19,676
|
Enterprise Value (EV)
1 |
22,431
|
26,335
|
46,771
|
28,192
|
14,979
|
14,555
|
P/E ratio
|
61.9
x
|
99.5
x
|
24.6
x
|
24.7
x
|
26.4
x
|
213
x
|
Yield
|
0.5%
|
0.15%
|
0.27%
|
0.4%
|
1.93%
|
0.21%
|
Capitalization / Revenue
|
9.46
x
|
9.82
x
|
6.06
x
|
5.32
x
|
3.01
x
|
4.52
x
|
EV / Revenue
|
8.84
x
|
9.4
x
|
5.57
x
|
4.17
x
|
2.13
x
|
3.35
x
|
EV / EBITDA
|
42
x
|
53.1
x
|
16.2
x
|
14.4
x
|
12.8
x
|
31.3
x
|
EV / FCF
|
-31.9
x
|
125
x
|
16.9
x
|
15.4
x
|
-23.3
x
|
-38.4
x
|
FCF Yield
|
-3.14%
|
0.8%
|
5.92%
|
6.49%
|
-4.28%
|
-2.61%
|
Price to Book
|
5.76
x
|
6.37
x
|
8.64
x
|
3.86
x
|
2.1
x
|
1.85
x
|
Nbr of stocks (in thousands)
|
400,100
|
400,100
|
396,100
|
409,914
|
409,914
|
409,914
|
Reference price
2 |
60.00
|
68.70
|
128.6
|
87.80
|
51.69
|
48.00
|
Announcement Date
|
4/24/19
|
4/24/20
|
4/25/21
|
4/22/22
|
3/30/23
|
4/12/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,536
|
2,800
|
8,397
|
6,766
|
7,046
|
4,350
|
EBITDA
1 |
534.5
|
496.2
|
2,891
|
1,951
|
1,172
|
464.7
|
EBIT
1 |
366.9
|
257.6
|
2,592
|
1,680
|
826.8
|
112.9
|
Operating Margin
|
14.46%
|
9.2%
|
30.86%
|
24.83%
|
11.73%
|
2.6%
|
Earnings before Tax (EBT)
1 |
474.9
|
328.2
|
2,442
|
1,746
|
1,007
|
115.5
|
Net income
1 |
386.6
|
276.3
|
2,090
|
1,462
|
802.9
|
92.9
|
Net margin
|
15.24%
|
9.87%
|
24.89%
|
21.6%
|
11.4%
|
2.14%
|
EPS
2 |
0.9700
|
0.6907
|
5.235
|
3.550
|
1.957
|
0.2253
|
Free Cash Flow
1 |
-703.6
|
210.8
|
2,767
|
1,829
|
-641.5
|
-379.3
|
FCF margin
|
-27.74%
|
7.53%
|
32.95%
|
27.03%
|
-9.1%
|
-8.72%
|
FCF Conversion (EBITDA)
|
-
|
42.49%
|
95.7%
|
93.73%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
76.3%
|
132.37%
|
125.15%
|
-
|
-
|
Dividend per Share
2 |
0.3000
|
0.1010
|
0.3500
|
0.3500
|
1.000
|
0.1000
|
Announcement Date
|
4/24/19
|
4/24/20
|
4/25/21
|
4/22/22
|
3/30/23
|
4/12/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,575
|
1,152
|
4,152
|
7,798
|
6,209
|
5,121
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-704
|
211
|
2,767
|
1,829
|
-642
|
-379
|
ROE (net income / shareholders' equity)
|
9.58%
|
6.44%
|
40.3%
|
19.1%
|
8.23%
|
0.93%
|
ROA (Net income/ Total Assets)
|
4.43%
|
2.89%
|
18.9%
|
8.25%
|
3.61%
|
0.5%
|
Assets
1 |
8,738
|
9,578
|
11,036
|
17,710
|
22,243
|
18,425
|
Book Value Per Share
2 |
10.40
|
10.80
|
14.90
|
22.70
|
24.60
|
26.00
|
Cash Flow per Share
2 |
2.670
|
1.840
|
13.70
|
16.10
|
12.60
|
12.50
|
Capex
1 |
678
|
626
|
301
|
384
|
1,267
|
1,236
|
Capex / Sales
|
26.74%
|
22.37%
|
3.59%
|
5.67%
|
17.98%
|
28.43%
|
Announcement Date
|
4/24/19
|
4/24/20
|
4/25/21
|
4/22/22
|
3/30/23
|
4/12/24
|
|
1st Jan change
|
Capi.
|
---|
| -11.15% | 2.24B | | -27.67% | 9.87B | | -17.30% | 2.74B | | -22.32% | 1.63B | | +59.69% | 1.39B | | +23.58% | 772M | | -1.31% | 760M | | -28.57% | 516M | | +5.37% | 310M | | +12.46% | 219M |
Bio Diagnostics & Testing
|